Cytek Biosciences, Inc.
NASDAQ•CTKB
CEO: Dr. Wenbin Jiang Ph.D.
セクター: Healthcare
業種: Medical - Devices
上場日: 2021-07-23
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
連絡先情報
時価総額
$514.20M
PER (TTM)
-7.7
27
配当利回り
--
52週高値
$6.18
52週安値
$2.37
52週レンジ
順位53Top 76.1%
2.8
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 2.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025
財務ダッシュボード
Q4 2025 データ
売上高
$62.14M+0.00%
直近4四半期の推移
EPS
-$0.34+0.00%
直近4四半期の推移
フリーCF
-$1.77M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Total Revenue Up 1% Net revenue reached $201.5M, driven by 21% service revenue growth, partially offset by 6% product revenue decline.
Service Revenue Strong Growth Service revenue increased $10.1M to $57.3M, reflecting installed base expansion and recurring revenue leverage.
Significant Net Loss Recorded Net loss widened to $(66.5M) in 2025, impacted by $33.6M valuation allowance on deferred tax assets.
FSP Platform Expansion Launched Cytek Aurora Evo system in May 2025; R&D spending decreased 7% to $36.5M.
リスク要因
High Dependency on Offerings Revenue highly dependent on core Cytek Aurora systems; slow sales cycles cause quarterly revenue fluctuations.
Supply Chain Single Source Risk Reliance on limited suppliers for key components like lasers; qualification of alternatives takes 12 to 24 months.
Increased Operating Expenses General and administrative expenses rose 37% to $58.9M, primarily due to higher patent litigation costs.
International Regulatory Exposure International operations face regulatory, political, and economic risks, including tariffs and export control compliance.
見通し
Accelerate Global Customer Adoption Plan to maximize sales infrastructure, increase marketing, and support entry into new markets globally.
Invest in Workflow Solutions Focus on integrated workflows and consumables pull-through to drive recurring revenue growth from installed base.
Drive Clinical Research Adoption Deep commitment to developing platform applications in disease detection, diagnosis, and treatment monitoring.
Capital Needs Uncertainty May need to raise additional capital to fund operations, product development, and geographic expansion plans.
同業比較
売上高 (TTM)
$854.40M
$822.31M
$701.20M
粗利益率 (最新四半期)
83.5%
80.6%
73.2%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| BFLY | $926.86M | -11.9 | -35.3% | 6.9% |
| AVNS | $624.54M | -9.2 | -8.6% | 12.0% |
| SRDX | $614.51M | -34.8 | -15.6% | 19.2% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
14.4%
安定成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
25%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年5月14日
EPS:-$0.04
|売上高:$43.95M
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし